Amarin Corp Plc (AMRN)

[ggwpq]

From your link of the Jardiance trial,

"After a median follow-up of about three years, about 10.5 percent of those getting Jardiance had suffered a heart attack or a stroke, or had died from cardiovascular causes, compared with 12.1 percent of those getting a placebo. That works out to about a 14 percent relative reduction in risk."

R-IT's events include soft MACE, therfore R-IT placebo group's annual event rate of over 5.2% seems very achievable.